Theracos, Inc.

Columbia University

Fujian Haixi Pharmaceuticals Co., Ltd

Dow Global Technolgoies LLC

Xiamen San'an Optoelectronics Co., Ltd

European Organisation for Astronomical Research in the Southern Hemisphere

Shanghai Meiyue Biotech Development Co., Ltd.

Jiaohong Biotechnology (shanghai) Co., Ltd.

Yan Feng

Brian Seed

Yuanwei Chen

Binhua Lv

Michael J Hadd

Baihua Xu

Jiyan Du

Donald W Landry

Shixian Deng

Ottavio Arancio

Jacques Y Roberge

Yuelin Wu

Huawei Cheng

Congna Wang

Yanli Song

Shengbin Li

Lili Zhang

Ge Xu

Jiajia Dong

Mauro Fa

Yitshak Francis

Min Xu

Kun Peng

Xinshan Kang

Xuan Gong

Joseph Gan

Qian Liu

Chung-Ying Chang

Chaodong Wang

Jole Fiorito

Yu-Tsai Teng

Ruyong Wang

Xiaolin Wang

Shanghai Yu

Zelin Sheng

Xinxing Tang

Shuo Yang

Qian He

Shutian Qiu

Wayne Zhang

Zhilong Hu

Vasanthakumar Rajappan

Michal Luzac

Sengen Sen

Shiqiang Li

Xin Lian

Jianjia Zheng

Yueli Fu

Junqing Li

Yuesheng Chong

Guanhua Xun

Domenico Bonaccini Calia

Zhonghong Wang

Fengsen Zhang

Patrick P Yan

Yizhang Ye

Binhua Xu

Feihong Dai

Luke R Taylor

Wolfgang Hackenberg

Ronald Holzlöhner

Yawen Ding

Provided are a method for detecting a nucleic acid based on prokaryotic Argonaute protein and an application thereof. In particular, provided is a system for detecting a target nucleic acid molecule. The system comprises guide ssDNA, a gene-editing enzymeArgonaute (PfAgo), and a fluorescent reporter nucleic acid.

Method for detecting nucleic acid based on prokaryotic argonaute protein and application thereof

Provided herein are compounds of formula (I) having activity on a receptor protein tyrosine kinase, wherein R, R, R, A, Q, Z, X and W are set forth in the description, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof.

Heteroaryl compounds as kinase inhibitor

A quaternary lactam compound of formula (I). The compound is used in the manufacture of a medicament for the treatment and/or prevention of thrombotic or thromboembolic disorders. 

Quaternary lactam compound and pharmaceutical use thereof

The present application provides a compound in formula III, and further provides a use of the compound in the synthesis of a Brivaracetam intermediate and a crude drug, and a synthesis method. A raw material involved in the method of the present application is low in costs and easily available; (R)-4-propyl-dihydrofuran-2-ketone having high optical purity can be prepared; complicated separation and purification steps are avoided; costs are reduced, and the method is more applicable to industrial production. 

Compound and use thereof in synthesis of brivaracetam intermediate and crude drug

A light emitting chip includes a first-type semiconductor layer, a light emitting layer, and a second-type semiconductor layer which are disposed in such order, a passivation layer, and a current spreading layer. The second-type semiconductor layer and the light emitting layer cooperate to form a mesa structure which partially exposes the first-type semiconductor layer. The mesa structure has a lateral surface over which the passivation layer is disposed. The current spreading layer is disposed in contact with the second-type semiconductor layer. A distance between peripheries of a contact surface of the current spreading layer and a top surface of the second-type semiconductor layer is not greater than 5 &#x3bc;m. A method for producing the chip is also disclosed.

Light emitting chip and method of producing the same

The invention provides for a method for screening compounds that bind to and modulate a histone acetyltransferase protein. The invention further provides methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein as well as cancer by administering a HAT-activating compound to a subject.

Histone acetyltransferase activators and uses thereof

The invention provides for compounds that are phosphodiesterase inhibitors. The invention further provides for a method for screening compounds that bind to and modulate a phosphosdiesterase protein. The invention also provides methods for treating conditions associated with accumulated amyloid-beta peptide deposit accumulations by administering a phosphodiesterase-binding compound to a subject.

Phosphodiesterase inhibitors and uses thereof

The invention provides compounds and compositions comprising compounds that modulate histone acyl transferase (HAT). The invention further provides methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein as well as cancer by administering a compound that modulates HAT to a subject.

Histone acetyltransferase modulators and uses thereof

Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions that are affected by SGLT inhibition.

Deuterated benzylbenzene derivatives and methods of use

A process comprising contacting a) an epoxy resin; b) an adduct comprising at least one oxazolidone ring prepared from a multifunctional epoxy resin and an isocyanate compound; and c) an unsaturated acid to form a vinyl ester, is disclosed.

Oxazolidone ring containing vinyl ester resin and products therefrom

Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.

Benzylbenzene derivatives and methods of use

Optical Raman fiber amplifier (), with an amplification fiber, wherein at least one section thereof has a ratio of Raman gain coefficient gto Brillouin ggain coefficient of g/glarger than 0.001 at the fiber operating temperature and a vacuum wavelength of 1064 nm. The invention further refers to a corresponding light source, the use of a fiber and a method of amplifying light.

Narrow band fiber Raman optical amplifier

Growing community of inventors

Shanghai, China

Yan Feng